|
Psoriasis
|
0.100 |
Biomarker
|
disease |
BEFREE |
More selective anti-IL23 agents (anti-p19) have shown efficacy and are being further developed, in contrast to agents inhibiting IL-17 downstream, which have failed in IBD clinical trials despite their clear efficacy in psoriasis.
|
31092171 |
2019 |
|
Psoriasis
|
0.100 |
Biomarker
|
disease |
BEFREE |
DISCUSSION: Because the concurrent existence of psoriatic arthritis and IBD is becoming increasingly appreciated in recent literature, healthcare providers should have a high index of suspicion in patients with psoriasis and psoriatic arthritis presenting with unusual intestinal symptoms.
|
31424717 |
2019 |
|
Psoriasis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Of these, 343,263 (19.6%) prescriptions for IBD, 92,343 (16.2%) prescriptions for RA, and 169,573 (6.9%) prescriptions for PSO were for biologicals.
|
31327630 |
2019 |
|
Psoriasis
|
0.100 |
Biomarker
|
disease |
BEFREE |
This review will focus on the interplay between IBD and PS, with details on prevalence and phenotype of PS in IBD, genetics, pathogenetic pathways, and therapy.
|
31079092 |
2019 |
|
Psoriasis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Given the frequent association of psoriasis and IBD, overlooking coexistent skin disease may lead to overestimating the frequency of these features.
|
28412702 |
2017 |
|
Psoriasis
|
0.100 |
Biomarker
|
disease |
BEFREE |
The overall prevalence rate of IBD and psoriasis was 2.4% ( n = 33), with 1.8% ( n = 25) in the Crohn's disease group and 0.6% ( n = 8) in the ulcerative colitis group.
|
28069913 |
2017 |
|
Psoriasis
|
0.100 |
Biomarker
|
disease |
BEFREE |
The RR (95% CI) in individuals with a first-degree relative with RA was 2.91 (2.49, 3.42) for SLE; 2.92 (1.62, 5.25) for SSc; 3.13 (2.50, 3.93) for primary SS; 0.95 (0.36, 2.51) for idiopathic inflammatory myositis; 1.96 (1.54, 2.48) for type 1 diabetes mellitus; 3.32 (1.82, 5.95) for multiple sclerosis; 1.31 (1.31, 2.43) for IBD; 2.76 (2.46, 3.10) for AS; and 1.65 (1.54, 1.77) for psoriasis.
|
28160009 |
2017 |
|
Psoriasis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Although there are many similarities among AS patients possessing HLA-B*27 versus those lacking this gene, the former group has a younger age of onset, a shorter delay in diagnosis, a better clinical response to tumor necrosis factor inhibitors, a greater familial occurrence, a greater risk for occurrence of acute anterior uveitis, and a lower risk for occurrence of psoriasis and IBD.
|
28386763 |
2017 |
|
Psoriasis
|
0.100 |
Biomarker
|
disease |
BEFREE |
At baseline, 39 (18%) patients had AAU, 15 (7%) had IBD and 9 (4%) had psoriasis.
|
25234663 |
2015 |
|
Psoriasis
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Clinical characteristics were comparable between IBD patients with or without psoriasis: age 50 [23-72] vs 47 [16-85]; IBD duration 9.5 [1-46] vs 9 [1-41]; p = non-significant].
|
25908719 |
2015 |
|
Psoriasis
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Genome-wide association studies (GWAS) in several populations have demonstrated significant association of the IL23R gene with IBD (Crohn's disease (CD) and ulcerative colitis (UC)) and psoriasis, suggesting that perturbation of the IL-23 signaling pathway is relevant to the pathophysiology of these diseases.
|
22022372 |
2011 |
|
Psoriasis
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
In the UK case-control study with new cases, four of the eight SNPs showed significant associations, whereas in the extended UK study, seven of the eight IL-23R SNPs showed significant associations (P < 0.05) with AS, maximal with rs11209032 (P < 10(-5), OR 1.3), when cases with IBD and/or psoriasis were excluded.
|
19189980 |
2009 |